Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 9, Issue 8, Pages 643-U24Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3184
Keywords
-
Funding
- Deutsche Krebshilfe
- Else-Kroner-Fresenius-Stiftung
- Carls-Stiftung
- LOEWE Centre Frankfurt
Ask authors/readers for more resources
The polo-like kinase 1 (PLK1) acts in concert with cyclin-dependent kinase 1-cyclin B1 and Aurora kinases to orchestrate a wide range of critical cell cycle events. Because PLK1 has been preclinically validated as a cancer target, small-molecule inhibitors of PLK1 have become attractive candidates for anticancer drug development. Although the roles of the closely related PLK2, PLK3 and PLK4 in cancer are less well understood, there is evidence showing that PLK2 and PLK3 act as tumour suppressors through their functions in the p53 signalling network, which guards the cell against various stress signals. In this article, recent insights into the biology of PLKs will be reviewed, with an emphasis on their role in malignant transformation, and progress in the development of small-molecule PLK1 inhibitors will be examined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available